News | October 10, 2025
Thermo Fisher launches new test to assess lung transplant rejection
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Subscribe To Our Newsletter & Stay Updated
